LEADS BIOLABS
Leads Biolabs is a pharmaceutical company that develops medicines and treatments for tumors.
LEADS BIOLABS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Website Url:
http://www.leadsbiolabs.com
Status:
Active
Contact:
025-83378099
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Amazon Amazon Virginia Region HiChina DNS
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
MitoZyme
MitoZyme is a pharmaceutical company that develops medicines to treat cardiometabolic diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Employees Featured
Founder
Investors List
Anjie Zhengjuan
Anjie Zhengjuan investment in Series C - Leads Biolabs
Lapam Capital
Lapam Capital investment in Series C - Leads Biolabs
Rongchang Chuangtou
Rongchang Chuangtou investment in Series C - Leads Biolabs
Beijing Hankang Chuangye Touzi
Beijing Hankang Chuangye Touzi investment in Series C - Leads Biolabs
Shenzhen Capital Group
Shenzhen Capital Group investment in Series C - Leads Biolabs
Loyal Valley Capital
Loyal Valley Capital investment in Series C - Leads Biolabs
Huaige Capital
Huaige Capital investment in Series C - Leads Biolabs
Enran Chuangtou
Enran Chuangtou investment in Series C - Leads Biolabs
Dyee Capital
Dyee Capital investment in Series C - Leads Biolabs
Gansu New Silk Road Industrial Investment
Gansu New Silk Road Industrial Investment investment in Series C - Leads Biolabs
Official Site Inspections
http://www.leadsbiolabs.com Semrush global rank: 7.02 M Semrush visits lastest month: 638
- Host name: ec2-52-0-214-55.compute-1.amazonaws.com
- IP address: 52.0.214.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Leads Biolabs"
– 南京维立志博生物科技股份有限公司
南京维立志博生物科技股份有限公司是一家临床阶段的生物科技公司，致力于创新疗法的发现、开发及商业化，以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗 …See details»
Nanjing Weili Zhibo Biotechnology Co., Ltd.
Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company founded in Nanjing by a team of senior U.S.-trained antibody drug developers. Since 2014, Our extensive R&D pipeline consist of more than twenty novel …See details»
Leads Biolabs - Crunchbase Company Profile & Funding
Leads Biolabs is a biotechnology company that develops treatment outcomes and access for patients worldwide. The company is committed to researching and developing novel antibody-based therapeutics in oncology and immunological …See details»
LEADS BioLabs - VentureRadar
Website: http://www.leadsbiolabs.com Develops novel biopharmaceutical solutions, focusing on over 10 mono-targeted and bispecific antibody drug projects for cancer immunotherapy and …See details»
Leads Biolabs Company Profile 2024: Valuation, Funding
Developer and provider of bio pharmaceutical products designed to create antibodies for the treatment of cancer. The company's research focuses on tumor immunotherapy antibody …See details»
NMPA and FDA Approved the First-in-Human Clinical Trial …
Jul 31, 2023 · Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company founded in Nanjing by a team of senior U.S.-trained antibody drug developers.See details»
Leads Biolab - Products, Competitors, Financials, Employees ...
Leads Biolab is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies for oncology, autoimmune diseases, and other …See details»
The U.S. FDA Approved the Phase I/II Clinical Trial Application to ...
Jun 16, 2023 · Nanjing Leads Biolabs Co., Ltd. is a clinical-stage R&D biotech company founded in Nanjing by a team of senior U.S.-educated antibody drug developers.See details»
Nanjing Leads Biolabs and BeiGene Announce Worldwide License …
Dec 13, 2021 · Nanjing Leads Biolabs (Leads Biolabs) is a clinical-stage US-Sino joint venture company, focusing on development and commercialization of second-generation immuno …See details»
Nanjing Weili Zhibo Biotechnology Co., Ltd. - Leads Biolabs
As the most authoritative and influential annual event in the field of oncology in China, CSCO consistently propels the advancement and development of oncology disciplines.See details»
Chime Biologics Forms mAb Development and Manufacturing
Jul 6, 2023 · Under the new three-way collaboration, Chime Biologics will cooperate with Leads Biolabs to accelerate the filing of an investigational new drug (IND) application and provide …See details»
Leads Biolabs Receives Orphan Drug Designation from the US FDA …
Nov 6, 2024 · By simultaneously binding to CD3 on T cells and the tumor-associated antigen GPRC5D on cancer cells, LBL-034 brings T cells into close proximity with cancer cells, …See details»
FDA approves IND application for Nanjing Leads Biolabs’ bispecific …
Jul 31, 2023 · US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) have approved the Investigational New Drug (IND) applications for …See details»
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio …
Nov 7, 2024 · Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody.See details»
Aditum Bio and Leads Biolabs Announce the Formation of
Nov 7, 2024 · Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody.See details»
NMPA and FDA Approved the First-in-Human Clinical ... - Markets …
NANJING, China, July 31, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as 'Leads Biolabs' or 'Company') announced ...See details»
Recommended Stories - Yahoo Finance
Nov 6, 2024 · LBL-034, a novel bispecific antibody designed using Leads Biolabs' proprietary T cell engager antibody technology platform "LeadsBody TM ", is the world's third GPRC5D …See details»
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio …
Nov 7, 2024 · OAKLAND and NANJING, NOVEMBER 7, 2024 – Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an …See details»
Leads Biolabs is Proud to Announce its Participation in the 2024 …
May 14, 2024 · Leads Biolabs will present the exciting clinical data on its four innovative clinical programs at the ASCO meeting.See details»
Chime Biologics Announces Strategic Cooperation with Leads …
SHANGHAI, June 30, 2023 /PRNewswire/ -- Chime Biologics, a leading CDMO that enables its partners' success in biologics, announced that it has established 3-way strategic cooperation …See details»